Published in Am J Cardiol on April 15, 2004
Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest (2011) 1.35
Novel therapeutic targets for hypertension. Nat Rev Cardiol (2010) 1.13
Aldosterone and glomerular podocyte injury. Clin Exp Nephrol (2008) 1.07
Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol (2013) 1.01
Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome. Clin Exp Nephrol (2010) 0.87
The effect of aldosterone blockade in patients with Alport syndrome. Pediatr Nephrol (2006) 0.87
Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis. Horm Metab Res (2008) 0.85
Effect of aldosterone and MR blockade on the brain and the kidney. Heart Fail Rev (2005) 0.84
Pathogenesis and therapeutic implications of cardiorenal syndrome. Clin Exp Nephrol (2010) 0.84
Role of mineralocorticoid receptor/Rho/Rho-kinase pathway in obesity-related renal injury. Int J Obes (Lond) (2011) 0.83
Mizoribine ameliorates renal injury and hypertension along with the attenuation of renal caspase-1 expression in aldosterone-salt-treated rats. PLoS One (2014) 0.81
The kidneys and aldosterone/mineralocorticoid receptor system in salt-sensitive hypertension. Curr Hypertens Rep (2011) 0.79
The Role of Aldosterone in Obesity-Related Hypertension. Am J Hypertens (2016) 0.77
Oxidative damages in tubular epithelial cells in IgA nephropathy: role of crosstalk between angiotensin II and aldosterone. J Transl Med (2011) 0.77
The autocrine/paracrine loop after myocardial stretch: mineralocorticoid receptor activation. Curr Cardiol Rev (2013) 0.77
TAK-242, a Toll-Like Receptor 4 Antagonist, Protects against Aldosterone-Induced Cardiac and Renal Injury. PLoS One (2015) 0.76
Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy. F1000Res (2017) 0.75
Pulsatile Cortisol Feedback on ACTH Secretion Is Mediated by the Glucocorticoid Receptor and Modulated by Gender. J Clin Endocrinol Metab (2016) 0.75
Aldosterone-to-renin ratio acts as the predictor distinguishing the primary aldosteronism from chronic kidney disease. Int J Clin Exp Pathol (2015) 0.75
Long-term use of aldosterone-receptor antagonists in uncontrolled hypertension: a retrospective analysis. Int J Hypertens (2011) 0.75
Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines! Front Cardiovasc Med (2015) 0.75
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med (2003) 13.25
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med (2009) 5.34
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care (2006) 4.91
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation (2003) 3.49
Chelation therapy for ischemic heart disease: a randomized controlled trial. JAMA (2002) 3.13
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab (2006) 2.64
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press (2013) 2.62
Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol (2003) 2.47
Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int (2008) 2.46
Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension (2003) 2.06
Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors. J Clin Hypertens (Greenwich) (2012) 2.03
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Can J Cardiol (2005) 2.03
Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain (2012) 1.94
The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2012) 1.86
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol (2013) 1.85
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol (2006) 1.67
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2009) 1.64
Reproducibility of the circadian blood pressure pattern in 24-h versus 48-h recordings: the Spanish Ambulatory Blood Pressure Monitoring Registry. J Hypertens (2007) 1.62
A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens (2011) 1.57
Parents' perceptions of research with newborns. J Perinatol (2002) 1.52
The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy. Can J Cardiol (2002) 1.49
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2007) 1.49
[Prevalence of target organ damage and metabolic abnormalities in resistant hypertension]. Med Clin (Barc) (2011) 1.42
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2006) 1.42
Brain death: resolving inconsistencies in the ethical declaration of death. Can J Anaesth (2003) 1.41
The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2011) 1.38
Influence of high cardiovascular risk in asymptomatic people on the duration and cost of sick leave: results of the ICARIA study. Eur Heart J (2013) 1.37
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens (2002) 1.36
Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen. Diabetes Technol Ther (2010) 1.22
Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension (2002) 1.18
Smoking cessation initiated during hospital stay for patients with coronary artery disease: a randomized controlled trial. CMAJ (2009) 1.16
Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project. Hypertension (2004) 1.11
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part I - blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2010) 1.07
Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol (2010) 1.05
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2008) 1.05
Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J (2005) 1.03
The 2001 Canadian recommendations for the management of hypertension: Part one--Assessment for diagnosis, cardiovascular risk, causes and lifestyle modification. Can J Cardiol (2002) 1.02
Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care (2003) 0.97
Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res (2006) 0.96
Systematic review of safety and tolerability of a complex micronutrient formula used in mental health. BMC Psychiatry (2011) 0.95
Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Cardiol (2006) 0.94
Attitudes of health-care providers towards research with newborn babies. J Perinatol (2004) 0.94
Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol (2003) 0.93
Effect of angiotensin receptor blockade on central haemodynamics in essential hypertension: results of a randomised trial. J Renin Angiotensin Aldosterone Syst (2008) 0.92
Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther (2003) 0.89
'Multiple action fixed combination. Present or future?'. Fundam Clin Pharmacol (2009) 0.88
Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. J Hypertens (2014) 0.85
Development of albuminuria and enhancement of oxidative stress during chronic renin-angiotensin system suppression. J Hypertens (2014) 0.84
Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. Am J Cardiovasc Drugs (2009) 0.83
Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke. J Hypertens (2016) 0.83
Clinical characteristics of isolated clinic hypertension. J Hypertens (2008) 0.82
AT1 blockers and uric acid metabolism: are there relevant differences? J Hypertens Suppl (2002) 0.82
Glycemic and insulinemic responses of nondiabetic healthy adult subjects to an experimental acid-induced viscosity complex incorporated into a glucose beverage. Nutrition (2002) 0.81
Should hypertension guidelines be changed for hypertensive patients with the metabolic syndrome? J Clin Hypertens (Greenwich) (2007) 0.80
Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy? J Clin Pharmacol (2003) 0.79
Atherosclerotic renovascular disease. Can J Cardiol (2006) 0.79
Prevalence of renal insufficiency in individuals with hypertension and obesity/overweight: the FATH study. J Am Soc Nephrol (2006) 0.79
A 16-week open-label, multicenter pilot study assessing insulin pump therapy in patients with type 2 diabetes suboptimally controlled with multiple daily injections. J Diabetes Sci Technol (2011) 0.78
[Ambulatory blood pressure monitoring (CABPM): clinical characteristics of 31,530 patients]. Med Clin (Barc) (2007) 0.77
Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase. Clin Drug Investig (2011) 0.76
Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension. Arch Intern Med (2003) 0.76
Antihypertensive therapy in patients with metabolic syndrome. Curr Opin Nephrol Hypertens (2006) 0.76
A review of the benefits of early treatment initiation with single-pill combinations of telmisartan with amlodipine or hydrochlorothiazide. Vasc Health Risk Manag (2013) 0.75
Does sodium reduction affect mortality? Can Fam Physician (2013) 0.75
Experience collecting interim data on mortality: an example from the RALES study. Curr Control Trials Cardiovasc Med (2001) 0.75
One step forward for serelaxin as a promising therapy in cardiac fibrosis. Hypertension (2014) 0.75
Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial. Am J Hypertens (2002) 0.75
Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors in hypertension and kidney disease. Can J Cardiol (2002) 0.75
[Effectiveness and safety of calcium antagonists in hypertensive patients]. Med Clin (Barc) (2005) 0.75
[Comorbidities in internal medicine]. Dtsch Med Wochenschr (2009) 0.75
Management of cardiovascular risk factors in patients with metabolic syndrome. Cardiovasc Hematol Agents Med Chem (2007) 0.75
[Renal function protection in type 2 diabetic patients]. Med Clin (Barc) (2002) 0.75
Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study. Curr Med Res Opin (2014) 0.75
[Stratification and degree of control of cardiovascular risk factors in hypertensive Spanish population. Results of the DICOPRESS study]. Med Clin (Barc) (2007) 0.75
[Prevention and regenerative mechanisms in internal diseases]. Med Klin (Munich) (2009) 0.75
[New targets in patients with cardiometabolic risk]. Med Clin (Barc) (2007) 0.75
An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy. Expert Opin Pharmacother (2005) 0.75
24-h pulse pressure cutoff point definition by office pulse pressure in a population of Spanish older hypertensive patients. J Hypertens (2017) 0.75
[Effectiveness of antihypertensive treatment and control of blood pressure: is it improvable?]. Med Clin (Barc) (2013) 0.75
Effectiveness and tolerability of a trandolapril-based antihypertensive treatment regimen over 12 months in actual clinical care across Canada. Clin Drug Investig (2013) 0.75
[Recent evidence of support to arterial hypertension treatment guides]. Med Clin (Barc) (2008) 0.75
[Selective inhibitors of cyclooxigenase-2 (Coxibs) and cardiovascular morbidity]. Med Clin (Barc) (2002) 0.75
[Therapy of hypertension. Cost conscious prevention of complications]. MMW Fortschr Med (2003) 0.75
[Can we achieve a greater reduction of cardiovascular mortality and morbidity in patients already treated with renin-angiotensin system blockers?]. Med Clin (Barc) (2009) 0.75
[Systolic hypertension-treat or not to treat?]. Herz (2003) 0.75